umu.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Sherif, Amir
Alternative names
Publications (10 of 11) Show all publications
Kirrander, P., Sherif, A., Friedrich, B., Lambe, M. & Håkansson, U. (2016). The Swedish National Penile Cancer Register: Incidence, Tumour Characteristics, Management and Survival. BJU International, 117(2), 287-292
Open this publication in new window or tab >>The Swedish National Penile Cancer Register: Incidence, Tumour Characteristics, Management and Survival
Show others...
2016 (English)In: BJU International, ISSN 1464-4096, E-ISSN 1464-410X, Vol. 117, no 2, p. 287-292Article in journal (Refereed) Published
Abstract [en]

OBJECTIVES:  To assess penile cancer incidence, stage distribution, adherence to guidelines, and prognostic factors in a population-based setting.

PATIENTS AND METHODS:  The population-based Swedish National Penile Cancer Register (NPECR) contains detailed information on tumour characteristics and management patterns. ● A total of 1678 men with primary squamous cell carcinoma of the penis identified in the NPECR between 2000 and 2012 were included in the study. 

RESULTS:  The mean age-adjusted incidence of penile cancer was 2.1/100,000 men, remaining virtually unchanged during the study period. At diagnosis, 14% and 2% were clinically N+ and M+, respectively. Most patients were staged pTis (34%), pT2 (19%), or pT1 (18%), whereas stage was unavailable in 18%. Organ-preserving treatment was used in 71% of Tis-T1 tumours. In cN0 and ≥pT1G2 patients, 50% underwent lymph node staging, while 74% of cN1-3 patients underwent lymph node dissection. The overall 5-year relative survival was 82%. Men aged ≥40 years and those with pT2-3, G2-3 and N+ tumours had worse outcome.

CONCLUSION: The incidence of penile cancer in Sweden is stable. Most men presented with localised disease, and the proportion of non-invasive tumours was high. During the period under study, adherence to guidelines was suboptimal. The overall 5-year relative survival was 82%. Older age, increasing tumour stage and grade, and increasing lymph node stage were associated with poorer survival.

Place, publisher, year, edition, pages
John Wiley & Sons, 2016
Keyword
penile cancer, population-based, incidence, TNM, prognostic factors, survival
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-96583 (URN)10.1111/bju.12993 (DOI)000367717300018 ()25395083 (PubMedID)
Note

Article first published online: 4 MAY 2015

Available from: 2014-11-24 Created: 2014-11-24 Last updated: 2017-12-05Bibliographically approved
Sherif, A., Hasan, M. N., Radecka, E., Rodriguez, A. L., Shabo, S., Karlsson, M., . . . Winqvist, O. (2015). Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. Scandinavian journal of urology, 49(6), 453-462
Open this publication in new window or tab >>Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer
Show others...
2015 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 49, no 6, p. 453-462Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: The aim of this study was to determine by computed tomography (CT) whether treatment with tumor-draining lymph-node-derived expanded autologous T lymphocytes results in objective responses and/or improved survival in patients with metastatic urinary bladder cancer (UBC) and to record the toxicity of the treatment.

MATERIALS AND METHODS: Eighteen patients with metastatic UBC were prospectively selected from two centers. The preoperative staging was T2-T4bN1-2 and/or M0-M1 or MX. Tumor-draining lymph nodes were harvested at intended cystectomy for the extraction of T lymphocytes. This was followed by expansion of the T lymphocytes in a cell culture, and subsequent reinfusion of these autologous tumor-specific T lymphocytes. Responses to therapy were evaluated by CT scans according to Response Evaluation Criteria In Solid Tumors (RECIST) and clinical follow-up, according to the research protocol.

RESULTS: Nine out of 18 patients were treated. Treatment was feasible and safe. In two out of nine immunologically treated patients, objective responses were detected in terms of diminished or obliterated nodal metastases. When excluding three patients with disseminated osseous metastases plus one with a T4b tumor left in situ, a success rate of two out of six treated patients was seen. The two responders had survival times of 35 and 11 months, respectively. No toxicity was recorded.

CONCLUSIONS: Infusion of expanded autologous tumor-specific T lymphocytes is feasible and safe, and objective responses according to RECIST were recorded. One objective responder to immunotherapy displayed notably long overall survival.

Keyword
Adoptive cellular immunotherapy, sentinel lymph-node biopsy, urinary bladder neoplasms
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:umu:diva-107501 (URN)10.3109/21681805.2015.1059880 (DOI)000365095200005 ()26144252 (PubMedID)
Available from: 2015-08-24 Created: 2015-08-24 Last updated: 2017-12-04Bibliographically approved
Witjes, J. A., Compérat, E., Cowan, N. C., De Santis, M., Gakis, G., Lebret, T., . . . Sherif, A. (2014). EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. European Urology, 65(4), 778-792
Open this publication in new window or tab >>EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
Show others...
2014 (English)In: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 65, no 4, p. 778-792Article in journal (Refereed) Published
Abstract [en]

CONTEXT: The European Association of Urology (EAU) guidelines panel on Muscle-invasive and Metastatic bladder cancer (BCa) updates its guidelines yearly. This updated summary provides a synthesis of the 2013 guidelines document, with emphasis on the latest developments.

OBJECTIVE: To provide graded recommendations on the diagnosis and treatment of patients with muscle-invasive BCa (MIBC), linked to a level of evidence.

EVIDENCE ACQUISITION: For each section of the guidelines, comprehensive literature searches covering the past 10 yr in several databases were conducted, scanned, reviewed, and discussed both within the panel and with external experts. The final results are reflected in the recommendations provided.

EVIDENCE SYNTHESIS: Smoking and work-related carcinogens remain the most important risk factors for BCa. Computed tomography (CT) and magnetic resonance imaging can be used for staging, although CT is preferred for pulmonary evaluation. Open radical cystectomy with an extended lymph node dissection (LND) remains the treatment of choice for treatment failures in non-MIBC and T2-T4aN0M0 BCa. For well-informed, well-selected, and compliant patients, however, multimodality treatment could be offered as an alternative, especially if cystectomy is not an option. Comorbidity, not age, should be used when deciding on radical cystectomy. Patients should be encouraged to actively participate in the decision-making process, and a continent urinary diversion should be offered to all patients unless there are specific contraindications. For fit patients, cisplatinum-based neoadjuvant chemotherapy should always be discussed, since it improves overall survival. For patients with metastatic disease, cisplatin-containing combination chemotherapy is recommended. For unfit patients, carboplatin combination chemotherapy or single agents can be used.

CONCLUSIONS: This 2013 EAU Muscle-invasive and Metastatic BCa guidelines updated summary aims to increase the quality of care and outcome for patients with muscle-invasive or metastatic BCa.

PATIENT SUMMARY: In this paper we update the EAU guidelines on Muscle-invasive and Metastatic bladder cancer. We recommend that chemotherapy be administered before radical treatment and that bladder removal be the standard of care for disease confined to the bladder.

Place, publisher, year, edition, pages
Elsevier, 2014
Keyword
EAU guidelines, Bladder cancer, Invasive, Infiltrative, Cystectomy, Bladder sparing treatments, Chemotherapy, Cisplatin-based, Comorbidities, Quality of life
National Category
Clinical Medicine
Identifiers
urn:nbn:se:umu:diva-84885 (URN)10.1016/j.eururo.2013.11.046 (DOI)000331716700023 ()24373477 (PubMedID)
Available from: 2014-01-22 Created: 2014-01-21 Last updated: 2018-02-13Bibliographically approved
Porserud, A., Sherif, A. & Tollbäck, A. (2014). The effects of a physical exercise programme after radical cystectomy for urinary bladder cancer. A pilot randomized controlled trial.. Clinical Rehabilitation, 28(5), 451-459
Open this publication in new window or tab >>The effects of a physical exercise programme after radical cystectomy for urinary bladder cancer. A pilot randomized controlled trial.
2014 (English)In: Clinical Rehabilitation, ISSN 0269-2155, E-ISSN 1477-0873, Vol. 28, no 5, p. 451-459Article in journal (Refereed) Published
Abstract [en]

Objective: Assessment of feasibility and effects of an exercise training programme in patients following cystectomy due to urinary bladder cancer.

Design: Single-blind, pilot, randomized controlled trial.Setting:University hospital, Sweden.

Subjects: Eighteen patients (64-78 years), of 89 suitable, cystectomized due to urinary bladder cancer, were randomized after hospital discharge to intervention or control.

Interventions: The 12-week exercise programme included group exercise training twice a week and daily walks. The control group received only standardized information at discharge.

Main outcome measures: Trial eligibility and compliance to inclusion were registered. Assessments of functional capacity, balance, lower body strength and health-related quality of life (HRQoL) with SF-36.

Results: Out of 122 patients 89 were eligible, but 64 did not want to participate/were not invited. Twenty-five patients were included, but 7 dropped out before randomization. Eighteen patients were randomized to intervention or control. Thirteen patients completed the training period. The intervention group increased walking distance more than the control group, 109 m (75-177) compared to 62 m (36-119) (P = 0.013), and role physical domain in SF-36 more than the control group (P = 0.031). Ten patients were evaluated one year postoperatively. The intervention group had continued increasing walking distance, 20 m (19-36), whereas the control group had shortened the distance -15.5 m (-43 to -5) (P = 0.010).

Conclusions: A 12-week group exercise training programme was not feasible for most cystectomy patients. However, functional capacity and the role-physical domain in HRQoL increased in the short and long term for patients in the intervention group compared with controls.

Place, publisher, year, edition, pages
Sage Publications, 2014
Keyword
Urinary bladder cancer, radical cystectomy, exercise
National Category
Clinical Medicine Cancer and Oncology Urology and Nephrology
Identifiers
urn:nbn:se:umu:diva-84886 (URN)10.1177/0269215513506230 (DOI)000334017700005 ()24249842 (PubMedID)
Available from: 2014-01-22 Created: 2014-01-21 Last updated: 2017-12-06Bibliographically approved
Bruins, H. M., Veskimae, E., Hernandez, V., Imamura, M., Neuberger, M. M., Dahm, P., . . . Witjes, J. A. (2014). The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. European Urology, 66(6), 1065-1077
Open this publication in new window or tab >>The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review
Show others...
2014 (English)In: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 66, no 6, p. 1065-1077Article in journal (Refereed) Published
Abstract [en]

CONTEXT: Controversy exists regarding the therapeutic value of lymphadenectomy (LND) in patients undergoing radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). OBJECTIVE: To systematically review the relevant literature assessing the impact of LND on oncologic and perioperative outcomes in patients undergoing RC for MIBC. EVIDENCE ACQUISITION: Medline, Medline In-Process, Embase, the Cochrane Central Register of Controlled Trials, and the Latin American and Caribbean Center on Health Sciences Information (LILACS) were searched up to December 2013. Comparative studies reporting on no LND, limited LND (L-LND), standard LND (S-LND), extended LND (E-LND), superextended LND (SE-LND), and oncologic and perioperative outcomes were included. Risk-of-bias and confounding assessments were performed. EVIDENCE SYNTHESIS: Twenty-three studies reporting on 19 793 patients were included. All but one study were retrospective. Planned meta-analyses were not possible because of study heterogeneity; therefore, data were synthesized narratively. There were high risks of bias and confounding across most studies as well as extreme heterogeneity in the definition of the anatomic boundaries of LND templates. All seven studies comparing LND with no LND favored LND in terms of better oncologic outcomes. Seven of 14 studies comparing (super)extended LND with L-LND or S-LND reported a beneficial outcome for (super)extended LND in at least a subset of patients. No difference in outcome was reported in two studies comparing E-LND and S-LND. The comparative harms of different extents of LND remain unclear. CONCLUSIONS: Although the quality of the data was poor, the available evidence indicates that any kind of LND is advantageous over no LND. Similarly, E-LND appears to be superior to lesser degrees of dissection, while SE-LND offered no additional benefits. It is hoped that data from ongoing randomized clinical trials will clarify remaining uncertainties. PATIENT SUMMARY: The current literature suggests that removal of lymph nodes in bladder cancer surgery is beneficial and might result in better outcomes in terms of prolonging survival; however, the quality of the available studies is poor, and high-quality studies are needed.

Place, publisher, year, edition, pages
Elsevier, 2014
Keyword
bladder neoplasms, radical cystectomy, lymphadenectomy, lymph node dissection, standard extended or superextended dissection, oncologic outcomes
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:umu:diva-95924 (URN)10.1016/j.eururo.2014.05.031 (DOI)000344694300030 ()25074764 (PubMedID)
Available from: 2014-11-07 Created: 2014-11-07 Last updated: 2017-12-05Bibliographically approved
Shah, C.-H., Viktorsson, K., Kanter, L., Sherif, A., Asmundsson, J., Rosenblatt, R., . . . Ullén, A. (2014). Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma. Urologic Oncology, 32(8), 1215-1224
Open this publication in new window or tab >>Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma
Show others...
2014 (English)In: Urologic Oncology, ISSN 1078-1439, E-ISSN 1873-2496, Vol. 32, no 8, p. 1215-1224Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: A major challenge in muscle-invasive urothelial carcinoma (UC) is to identify biomarkers that can predict disease prognosis and treatment response after cystectomy. Therefore, we analyzed the potential prognostic value of the proteins vascular endothelial growth factor receptor 2 (VEGFR2), S100A4, and S100A6 in UC.

METHODS: Retrospective outcome data and tumor specimens from 83 cystectomy patients with histologically confirmed invasive UC were included. Expression levels of VEGFR2 (also called flk-1 and KDR), S100A4, and S100A6 were analyzed in primary tumor tissue by immunohistochemistry.

RESULTS: Immunohistochemical staining and analysis of VEGFR2, S100A4, and S100A6 showed localization mainly in tumor cell cytoplasm. High VEGFR2 expression and low tumor category were independent variables associated with longer overall survival (OS) and disease-free survival, revealed by a bivariate Cox proportional hazards regression model (both P<0.001). In addition, the univariate log-rank test and the Cox model demonstrated that OS beyond 2 years was significantly greater among patients with low S100A6 expression than in those with high S100A6 expression (P = 0.017 and 0.022, respectively). Differences in tumor expression of S100A4 were not significantly associated with outcome.

CONCLUSION: In this study, VEGFR2 expression was significantly correlated with risk of disease relapse and OS in a defined cohort of patients with UC of the bladder treated by cystectomy.

Place, publisher, year, edition, pages
Elsevier, 2014
Keyword
Advanced urothelial carcinoma, S100A4, S100A6, VEGFR2
National Category
Urology and Nephrology Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-95923 (URN)10.1016/j.urolonc.2014.04.015 (DOI)000346627300018 ()24880461 (PubMedID)
Available from: 2014-11-07 Created: 2014-11-07 Last updated: 2017-12-05Bibliographically approved
Gakis, G., Witjes, J. A., Comperat, E., Cowan, N. C., De Santis, M., Lebret, T., . . . Sherif, A. M. (2013). EAU Guidelines on Primary Urethral Carcinoma. European Urology, 64(5), 823-830
Open this publication in new window or tab >>EAU Guidelines on Primary Urethral Carcinoma
Show others...
2013 (English)In: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 64, no 5, p. 823-830Article in journal (Refereed) Published
Abstract [en]

Context: The European Association of Urology (EAU) Guidelines Group on Muscle-Invasive and Metastatic Bladder Cancer prepared these guidelines to deliver current evidence-based information on the diagnosis and treatment of patients with primary urethral carcinoma (UC).

Objective: To review the current literature on the diagnosis and treatment of patients with primary UC and assess its level of scientific evidence.

Evidence acquisition: A systematic literature search was performed to identify studies reporting urethral malignancies. Medline was searched using the controlled vocabulary of the Medical Subject Headings database, along with a free-text protocol.

Evidence synthesis: Primary UC is considered a rare cancer, accounting for <1% of all malignancies. Risk factors for survival include age, tumour stage and grade, nodal stage, presence of distant metastasis, histologic type, tumour size, tumour location, and modality of treatment. Pelvic magnetic resonance imaging is the preferred method to assess the local extent of urethral tumour; computed tomography of the thorax and abdomen should be used to assess distant metastasis. In localised anterior UC, urethra-sparing surgery is an alternative to primary urethrectomy in both sexes, provided negative surgical margins can be achieved. Patients with locally advanced UC should be discussed by a multidisciplinary team of urologists, radiation oncologists, and oncologists. Patients with noninvasive UC or carcinoma in situ of the prostatic urethra and prostatic ducts can be treated with a urethra-sparing approach with transurethral resection and bacillus Calmette-Guerin (BCG). Cystoprostatectomy with extended pelvic lymphadenectomy should be reserved for patients not responding to BCG or as a primary treatment option in patients with extensive ductal or stromal involvement.

Conclusions: The 2013 guidelines document on primary UC is the first publication on this topic by the EAU. It aims to increase awareness in the urologic community and provide scientific transparency to improve outcomes of this rare urogenital malignancy.

Place, publisher, year, edition, pages
Elsevier, 2013
Keyword
Urethral carcinoma, Primary, Urethral neoplasms, Squamous cell carcinoma, Cytology, Cystoscopy, MRI, Biopsy, Urethral stricture, Penile-preserving surgery, Urethra-sparing surgery, Chemotherapy, Radiotherapy, EAU, Guidelines
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:umu:diva-82796 (URN)10.1016/j.eururo.2013.03.044 (DOI)000325478100031 ()
Available from: 2013-11-12 Created: 2013-11-11 Last updated: 2017-12-06Bibliographically approved
Zirakzadeh, A. A., Marits, P., Sherif, A. & Winqvist, O. (2013). Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies. Journal of Immunology, 190(11), 5847-5855
Open this publication in new window or tab >>Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies
2013 (English)In: Journal of Immunology, ISSN 0022-1767, E-ISSN 1550-6606, Vol. 190, no 11, p. 5847-5855Article in journal (Refereed) Published
Abstract [en]

B lymphocytes contribute to immune surveillance, by tumor-specific Abs and Ag presentation to T lymphocytes, but are insufficiently studied in humans. In this article, we report a flow cytometric investigation of B lymphocyte subpopulations in blood, lymph nodes (LNs), and malignant tissues from 20 patients operated on because of advanced solid tumors. The CD19(+) compartment in peripheral blood was essentially unaltered in patients, as compared with healthy control subjects. In metastatic LNs, signs of B lymphocyte activation were observed, as evidenced by increased proportions of plasmablasts and CD86-expressing cells. In tumor-infiltrating B lymphocytes (TIL-B), both switched memory cells and plasmablasts were expanded, as compared with nonmalignant epithelium. Moreover, pronounced skewing of Ig lambda/Ig kappa ratio was evident among TIL-Bs. By spectratype analysis on IgH, we confirmed a monoclonal expansion of the Vh7 family in TIL-B, also present in a tumor-associated LN. Sequencing the clonally expanded Vh7 revealed signs of somatic hypermutation. In conclusion, B lymphocytes in cancer patients exhibit signs of activation in tumor-associated tissues, likely induced by recognition of tumor Ags. Increased numbers of switched memory cells and plasmablasts in combination with clonal expansion and signs of somatic hypermutation suggest a CD4(+) T lymphocyte-dependent antitumoral response, which may be exploited for immunotherapy.

National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-76793 (URN)10.4049/jimmunol.1203279 (DOI)000319205900056 ()
Available from: 2013-07-16 Created: 2013-07-15 Last updated: 2017-12-06Bibliographically approved
Marits, P., Zirakzadeh, A. A., Sherif, A. & Winqvist, O. (2013). Response to Comment on "Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies" [Letter to the editor]. Journal of Immunology, 191(9), 4471-4472
Open this publication in new window or tab >>Response to Comment on "Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies"
2013 (English)In: Journal of Immunology, ISSN 0022-1767, E-ISSN 1550-6606, Vol. 191, no 9, p. 4471-4472Article in journal, Letter (Refereed) Published
Place, publisher, year, edition, pages
American Association of Immunologists, 2013
National Category
Immunology in the medical area
Identifiers
urn:nbn:se:umu:diva-83086 (URN)10.4049/jimmunol.1390053 (DOI)000325929000002 ()
Available from: 2013-11-18 Created: 2013-11-18 Last updated: 2018-01-11Bibliographically approved
Hu, J., Kinn, J., Zirakzadeh, A. A., Sherif, A., Norstedt, G., Wikstrom, A.-C. -. & Winqvist, O. (2013). The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clinical and Experimental Immunology, 172(3), 490-499
Open this publication in new window or tab >>The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation
Show others...
2013 (English)In: Clinical and Experimental Immunology, ISSN 0009-9104, E-ISSN 1365-2249, Vol. 172, no 3, p. 490-499Article in journal (Refereed) Published
Abstract [en]

Recent studies indicate that chemotherapeutic agents may increase the anti-tumoral immune response. Based on the pivotal role of dendritic cells (DCs) in host tumour-specific immune responses, we investigated the effect of commonly used chemotherapeutic drugs dexamethasone, doxorubicin, cisplatin and irinotecan and glucocorticoids on monocyte-derived DCs (moDCs). Dexamethasone displayed the strongest inhibitory effect on DC differentiation. The effect of cisplatin and irinotecan was moderate, while only weak effects were noticed for doxorubicin. Surprisingly, when the functional consequence of chemotherapy-treated CD14+ monocytes and their capacity to activate CD4+ T responders cells were investigated, cisplatin-treated monocytes gave rise to increased T cell proliferation. However, dexamethasone, doxorubicin and irinotecan-pretreated monocytes did not stimulate any increased T cell proliferation. Further investigation of this observation revealed that cisplatin treatment during DC differentiation up-regulated significantly the interferon (IFN)- transcript. By contrast, no effect was evident on the expression of interleukin (IL)-1, tumour necrosis factor (TNF)-, IL-6 or IFN- transcripts. Blocking IFN- attenuated the cisplatin-enhanced T cell proliferation significantly. In conclusion, cisplatin treatment enhanced the immune stimulatory ability of human monocytes, a mechanism mediated mainly by the increased production of IFN-.

Keyword
antigen presentation, chemotherapeutic drugs, cisplatin, dendritic cell, immunotherapy
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:umu:diva-71582 (URN)10.1111/cei.12060 (DOI)000318073000015 ()
Available from: 2013-06-05 Created: 2013-06-04 Last updated: 2017-12-06Bibliographically approved
Organisations

Search in DiVA

Show all publications